Enterovirus 68 future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
Line 4: Line 4:


==Overview==
==Overview==
Even though the treatment for enteroviruz infection is currently with supportive care, the development of other medical therapies has increased in the past years.  Immune globulin has shown clinical and laboratory improvement among some patients with enterovirus infection.  Antiviral medications, such as Pleconaril, are currently under investigation, but have shown benefit in patients with severe infections due to other subtypes of enterovirus.


==Future or Investigational Therapies==
==Future or Investigational Therapies==

Revision as of 18:29, 8 September 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]

Enterovirus 68 Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Risk Factors

Differentiating Enterovirus 68 from other Diseases

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Ultrasound

Chest X Ray

CT Scan

MRI

Treatment

Medical Therapy

Surgery

Primary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Enterovirus 68 future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Enterovirus 68 future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Enterovirus 68 future or investigational therapies

CDC on Enterovirus 68 future or investigational therapies

Enterovirus 68 future or investigational therapies in the news

Blogs on Enterovirus 68 future or investigational therapies

Directions to Hospitals Treating Enterovirus 68

Risk calculators and risk factors for Enterovirus 68 future or investigational therapies

Overview

Even though the treatment for enteroviruz infection is currently with supportive care, the development of other medical therapies has increased in the past years. Immune globulin has shown clinical and laboratory improvement among some patients with enterovirus infection. Antiviral medications, such as Pleconaril, are currently under investigation, but have shown benefit in patients with severe infections due to other subtypes of enterovirus.

Future or Investigational Therapies

Immune globulin

  • Studies in neonates with enterovirus infection suggest a possible benefit of the use of immune globulin in the treatment of this viral infection[1][2], however, more studies need to be done do confirm the benefit of this treatment.
  • The development of IVIG with high levels of enterovirus antibody has shown benefit in in vitro and mouse models studies for enterovirus subtype 71, however, this has not been studied for subtype 68.[3]

Antiviral Medication

  • Pleconaril has shown benefit in patients with severe life-threatening enterovirus infections. This antiviral drug prevents the attachment of the virus to the host cell and integration of its RNA to the host DNA. [4]
  • The table shown below describes the possible targets for antiviral treatment against enterovirus infections.[5][6]
Target Antiviral Drugs
Protease 2A or 3C Rupintrivir, Br-UTP, AG7088 derivative
Capsid binders Pleconaril, Pirodavirb, pyridazinyl oxime ethersb (BTA-39c), pyridyl imidazolidinonesc; NF-449c, V-073
RNA replication Enviroxime, TTP-8307, vinylacetylene analogs, GW5074c, Benzimidazoles, N(6)-benzyladenosine, metrifudil
RNA polymerase 2′C–Me-cytidine, 4′-azidocytidine, 2′C-ME-adenosine, ribavirin, DTriP-22c, aurintricarboxylic acid, gliotoxin, amiloride
Proteins involved in replication & assembly Brefeldin A, geldenamycin, 17AAG
Adapted from "The enteroviruses: Problems in need of treatments"[7]

References

  1. Marc Tebruegge & Nigel Curtis (2009). "Enterovirus infections in neonates". Seminars in fetal & neonatal medicine. 14 (4): 222–227. doi:10.1016/j.siny.2009.02.002. PMID 19303380. Unknown parameter |month= ignored (help)
  2. M. J. Abzug, H. L. Keyserling, M. L. Lee, M. J. Levin & H. A. Rotbart (1995). "Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 20 (5): 1201–1206. PMID 7620000. Unknown parameter |month= ignored (help)
  3. Rui-Yuan Cao, Jian-Feng Han, Tao Jiang, Xue Tian, Man Yu, Yong-Qiang Deng, E.-De Qin & Cheng-Feng Qin (2011). "In vitro and in vivo characterization of a new enterovirus type 71-specific human intravenous immunoglobulin manufactured from selected plasma donors". Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 51 (4): 246–249. doi:10.1016/j.jcv.2011.05.002. PMID 21641277. Unknown parameter |month= ignored (help)
  4. Rotbart, H. A.; Webster, A. D. (2001). "Treatment of Potentially Life-Threatening Enterovirus Infections with Pleconaril". Clinical Infectious Diseases. 32 (2): 228–235. doi:10.1086/318452. ISSN 1058-4838.
  5. Thibaut, Hendrik Jan; Leyssen, Pieter; Puerstinger, Gerhard; Muigg, Alexandra; Neyts, Johan; De Palma, Armando Mirko (2011). "Towards the design of combination therapy for the treatment of enterovirus infections". Antiviral Research. 90 (3): 213–217. doi:10.1016/j.antiviral.2011.03.187. ISSN 0166-3542.
  6. Hendrik Jan Thibaut, Armando M. De Palma & Johan Neyts (2012). "Combating enterovirus replication: state-of-the-art on antiviral research". Biochemical pharmacology. 83 (2): 185–192. doi:10.1016/j.bcp.2011.08.016. PMID 21889497. Unknown parameter |month= ignored (help)
  7. Abzug, Mark J. (2014). "The enteroviruses: Problems in need of treatments". Journal of Infection. 68: S108–S114. doi:10.1016/j.jinf.2013.09.020. ISSN 0163-4453.